ArticleTransplantation and cellular therapy2021

Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden.

Robert F Cornell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.